Market Summary
USD41.21-0.14
Market Closed-0.34%
TXG Stock Price
TXG RSI Chart
TXG Valuation
TXG Price/Sales (Trailing)
TXG Profitability
TXG Fundamentals
TXG Revenue
TXG Earnings
Price Action
52 Week Range
23.8163.57
(Low)(High)
Last 7 days
-10.8%
Last 30 days
-13.9%
Last 90 days
-24.5%
Trailing 12 Months
42.6%
TXG Financial Health
TXG Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TXG
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-14 | Saxonov Serge | gifted | - | - | -3,167 | chief executive officer |
2023-09-14 | Saxonov Serge | sold | -98,739 | 49.3697 | -2,000 | chief executive officer |
2023-08-22 | McAnear Justin J. | sold | -76,820 | 45.7811 | -1,678 | chief financial officer |
2023-08-22 | Saxonov Serge | sold | -172,000 | 45.7811 | -3,757 | chief executive officer |
2023-08-22 | Hindson Benjamin J. | sold | -157,899 | 45.7811 | -3,449 | see remarks |
2023-08-22 | Wilbur James | sold | -444,031 | 45.7811 | -9,699 | chief commercial officer |
2023-08-14 | Saxonov Serge | sold | -100,212 | 50.106 | -2,000 | chief executive officer |
2023-08-01 | Hindson Benjamin J. | sold | -433,612 | 62.2112 | -6,970 | see remarks |
2023-08-01 | Hindson Benjamin J. | acquired | 80,015 | 11.48 | 6,970 | see remarks |
2023-07-19 | Hindson Benjamin J. | acquired | 76,491 | 5.4872 | 13,940 | see remarks |
Which funds bought or sold TXG recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 85.62 | 559,000 | 1,208,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -94.94 | -55,452 | 2,960 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -34.39 | -300,751 | 575,152 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 64.00 | 1,099,900 | 2,803,720 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 6.01 | 346,097 | 6,016,150 | 0.01% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 3,000 | 4,128,000 | 0.04% |
2023-08-21 | VitalStone Financial, LLC | unchanged | - | -1,000 | - | -% |
2023-08-16 | CASTLEARK MANAGEMENT LLC | new | - | 3,423,550 | 3,423,550 | 0.16% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -0.78 | -99,014 | 14,219,000 | -% |
2023-08-15 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | reduced | -9.21 | -234,000 | 2,319,000 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of 10x Genomics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 10, 2023 | morgan stanley | 5.2% | 5,139,461 | SC 13G/A | |
| Jul 10, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 14, 2023 | venrock associates vi, l.p. | 4.9% | 4,828,247 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.81% | 8,420,011 | SC 13G/A | |
| Feb 08, 2023 | morgan stanley | 10.4% | 9,894,979 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 5.6% | 5,319,179 | SC 13G/A | |
| Jan 18, 2023 | baillie gifford & co | 9.00% | 8,602,235 | SC 13G/A | |
| Sep 12, 2022 | morgan stanley | 10.9% | 10,341,753 | SC 13G/A | |
| May 09, 2022 | blackrock inc. | 10.9% | 10,227,673 | SC 13G |
Recent SEC filings of 10x Genomics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 16, 2023 | 4 | Insider Trading | |
| Aug 04, 2023 | 10-Q | Quarterly Report | |
| Aug 03, 2023 | 4 | Insider Trading | |
| Aug 03, 2023 | 8-K | Current Report |
Peers (Alternatives to 10x Genomics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 32.8B | 7.0B | -6.47% | -9.35% | 28.95 | 4.69 | 5.03% | -14.68% |
MTD | 24.5B | 4.0B | -4.51% | -0.85% | 27.61 | 6.21 | 2.30% | 16.37% |
ILMN | 20.8B | 4.5B | -16.87% | -30.97% | -4.96 | 4.65 | -4.92% | -21931.58% |
PKI | 16.1B | 2.8B | -15.95% | -22.45% | 19.74 | 5.69 | -24.31% | 21.35% |
WAT | 16.0B | 3.0B | -0.88% | -1.65% | 23.72 | 5.35 | 3.16% | -3.93% |
| MID-CAP | ||||||||
| SMALL-CAP | ||||||||
PACB | 2.1B | 146.1M | -14.72% | 60.53% | -6.64 | 14.5 | 4.72% | -55.19% |
QTRX | 974.5M | 112.0M | 4.60% | 206.26% | -14.81 | 8.7 | 0.83% | 16.42% |
ADPT | 734.8M | 189.6M | -17.53% | -21.85% | -3.85 | 3.88 | 18.74% | 17.75% |
HBIO | 174.6M | 114.1M | -5.10% | 58.53% | -32.16 | 1.53 | -5.49% | -48.58% |
CDXS | 104.7M | 99.2M | -9.09% | -75.61% | -1.85 | 1.06 | -26.56% | -199.52% |
BNGO | 99.1M | 31.5M | -3.25% | 60.22% | -0.68 | 3.14 | 35.12% | -38.47% |
NSTG | 78.4M | 143.9M | -41.49% | -87.32% | -0.47 | 0.54 | 0.71% | -18.99% |
CSBR | 72.9M | 52.7M | -18.03% | -31.52% | -9.65 | 1.38 | 2.10% | -1984.29% |
PSNL | 59.2M | 67.1M | -18.67% | -60.39% | -0.54 | 0.88 | -12.13% | -17.68% |
10x Genomics News
Returns for TXG
Cumulative Returns on TXG
-30.8%
3-Year Cumulative Returns
Risks for TXG
What is the probability of a big loss on TXG?
88.3%
Probability that 10x Genomics stock will be more than 20% underwater in next one year
65.7%
Probability that 10x Genomics stock will be more than 30% underwater in next one year.
59.6%
Probability that 10x Genomics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TXG drawdown profile look like?
Y-axis is the maximum loss one would have experienced if 10x Genomics was unfortunately bought at previous high price.
Drawdowns
Financials for 10x Genomics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 6.0% | 568,408,000 | 536,198,000 | 516,409,000 | 503,707,000 | 497,932,000 | 499,165,000 | 490,490,000 | 459,178,000 | 405,698,000 | 332,761,000 | 298,845,000 | 261,916,000 | 251,306,000 | 264,220,000 | 245,893,000 | 221,158,000 | 196,558,000 | 172,483,000 | 146,313,000 | 127,678,667 | 118,304,000 |
| Gross Profit | 3.1% | 418,102,000 | 405,395,000 | 396,023,000 | 392,550,000 | 392,634,000 | 416,656,000 | 416,399,000 | 393,788,000 | 350,415,000 | 272,341,000 | 240,377,000 | 205,763,000 | 194,084,000 | 202,044,000 | 184,860,000 | 161,807,000 | 147,446,000 | 133,827,000 | 117,652,000 | 109,330,667 | 101,264,000 |
| Operating Expenses | 2.2% | 596,540,000 | 583,592,000 | 563,967,000 | 553,228,000 | 529,195,000 | 500,428,000 | 468,652,000 | 839,794,000 | 845,797,000 | 796,815,000 | 774,519,000 | 338,402,000 | 270,564,000 | 249,466,000 | 215,433,000 | 259,265,000 | 250,741,000 | 266,088,000 | 228,416,000 | 185,196,000 | - |
| S&GA Expenses | 3.9% | 327,078,000 | 314,905,000 | 298,300,000 | 289,290,000 | 277,965,000 | 267,331,000 | 257,560,000 | 243,657,000 | 233,130,000 | 208,843,000 | 202,326,000 | 185,108,000 | 166,173,000 | 154,328,000 | 130,834,000 | 118,984,000 | 105,480,000 | 97,212,000 | 87,936,000 | 76,440,000 | - |
| EBITDA | 100.0% | - | -143,905,000 | -136,127,000 | -136,357,000 | -113,325,000 | -60,963,000 | -31,731,000 | -426,124,000 | -476,665,000 | -507,931,000 | -518,782,000 | -117,583,000 | -63,155,000 | -36,000,000 | -20,888,000 | -91,603,000 | -98,403,666 | -119,324,000 | -106,084,000 | -54,660,000 | -13,625,000 |
| EBITDA Margin | 100.0% | - | -0.27 | -0.26 | -0.27 | -0.23 | -0.12 | -0.06 | -0.93 | -1.17 | -1.53 | -1.74 | -0.45 | -0.25 | -0.14 | -0.08 | -0.41 | -0.50 | -0.69 | -0.73 | -0.43 | -0.12 |
| Interest Expenses | -28.3% | 263,000 | 367,000 | 476,000 | 568,000 | 673,000 | 773,000 | 866,000 | 966,000 | 1,144,000 | 1,241,000 | 1,682,000 | 2,357,000 | 2,668,000 | 3,057,000 | 3,079,000 | 2,775,000 | 2,726,000 | 2,708,000 | 2,409,000 | 2,636,000 | - |
| Earnings Before Taxes | 1.8% | -166,867,000 | -169,931,000 | -161,971,000 | -161,553,000 | -138,166,000 | -84,293,000 | -53,715,000 | -446,345,000 | -494,960,000 | -524,747,000 | -534,476,000 | -132,879,000 | -77,211,000 | -48,276,000 | -31,033,000 | -99,489,000 | -105,223,000 | -125,884,000 | -112,398,000 | -61,316,000 | - |
| EBT Margin | 100.0% | - | -0.32 | -0.31 | -0.32 | -0.28 | -0.17 | -0.11 | -0.97 | -1.22 | -1.58 | -1.79 | -0.51 | -0.31 | -0.18 | -0.13 | -0.45 | -0.54 | -0.73 | -0.77 | -0.48 | -0.16 |
| Net Income | 1.2% | -172,290,000 | -174,334,000 | -166,000,000 | -167,234,000 | -142,491,000 | -89,085,000 | -58,223,000 | -455,347,000 | -504,024,000 | -533,139,000 | -542,731,000 | -134,292,000 | -78,047,000 | -48,758,000 | -31,251,000 | -99,641,000 | -105,383,000 | -100,428,000 | -112,485,000 | -49,281,333 | -43,232,000 |
| Net Income Margin | 100.0% | - | -0.33 | -0.32 | -0.33 | -0.29 | -0.18 | -0.12 | -0.99 | -1.24 | -1.60 | -1.82 | -0.51 | -0.31 | -0.18 | -0.13 | -0.45 | -0.54 | -0.58 | -0.77 | -0.39 | -0.37 |
| Free Cashflow | 100.0% | - | -125,013,000 | -165,267,000 | -161,069,000 | -161,376,000 | -128,642,000 | -122,651,000 | -252,352,000 | -262,047,000 | -286,856,000 | -254,564,000 | -102,906,000 | -45,920,000 | -18,721,000 | -8,115,000 | -61,662,000 | -83,346,666 | -106,904,000 | -82,693,000 | -39,053,333 | -14,455,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
| Assets | -2.4% | 990 | 1,014 | 1,029 | 996 | 1,002 | 1,003 | 1,019 | 991 | 978 | 954 | 929 | 1,043 | 583 | 610 | 46.00 | 573 | 124 |
| Current Assets | -3.1% | 583 | 602 | 635 | 629 | 666 | 697 | 748 | 744 | 757 | 746 | 774 | 900 | 452 | 430 | 481 | 474 | 106 |
| Cash Equivalents | -2.6% | 331 | 340 | 227 | 242 | 282 | 320 | 596 | 609 | 649 | 644 | 689 | 834 | 404 | 432 | 476 | 477 | 70.00 |
| Inventory | 1.7% | 84.00 | 82.00 | 82.00 | 79.00 | 71.00 | 64.00 | 60.00 | 51.00 | 44.00 | 39.00 | 30.00 | 25.00 | 22.00 | 19.00 | 15.00 | 13.00 | 9.00 |
| Net PPE | -2.5% | 285 | 292 | 289 | 258 | 223 | 190 | 169 | 143 | 122 | 107 | 73.00 | 65.00 | 56.00 | 52.00 | 49.00 | 47.00 | 11.00 |
| Goodwill | 0% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - |
| Liabilities | -7.2% | 196 | 212 | 223 | 220 | 218 | 197 | 201 | 190 | 193 | 202 | 190 | 217 | 192 | 201 | 186 | 151 | 101 |
| Current Liabilities | -12.4% | 98.00 | 112 | 131 | 127 | 118 | 94.00 | 110 | 100 | 113 | 121 | 118 | 146 | 122 | 59.00 | 63.00 | 48.00 | 32.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.00 | 7.00 | 4.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00 | 22.00 | 25.00 |
| Shareholder's Equity | -1.1% | 793 | 802 | 806 | 776 | 784 | 807 | 818 | 800 | 785 | 752 | 739 | 825 | 391 | 409 | 420 | 421 | - |
| Retained Earnings | -5.8% | -1,142 | -1,080 | -1,029 | -1,012 | -970 | -905 | -863 | -844 | -827 | -816 | -805 | -389 | -323 | -283 | -262 | -255 | -231 |
| Additional Paid-In Capital | 2.8% | 1,937 | 1,884 | 1,839 | 1,793 | 1,758 | 1,715 | 1,681 | 1,645 | 1,612 | 1,569 | 1,544 | 1,215 | 715 | 693 | 682 | 677 | 11.00 |
| Accumulated Depreciation | - | 86.00 | - | 69.00 | - | - | - | 49.00 | 44.00 | 39.00 | 35.00 | 31.00 | - | - | - | 19.00 | - | 14.00 |
| Shares Outstanding | 0.9% | 117 | 116 | 115 | 114 | 114 | 113 | 113 | 111 | 110 | 109 | 108 | 101 | 99.00 | 97.00 | 96.00 | 20.00 | 13.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2017Q4 |
| Cashflow From Operations | 32.1% | -11.49 | -16.93 | -33.61 | -41.52 | -58.18 | -38.09 | -21.37 | -157 | -186 | -219 | -217 | -81.02 | -10.87 | 23.00 | 35.00 | -23.07 | -50.13 | -83.36 | -76.41 | -33.88 | -10.70 |
| Share Based Compensation | 6.1% | 162 | 153 | 137 | 123 | 115 | 106 | 96.00 | 83.00 | 71.00 | 58.00 | 49.00 | 39.00 | 30.00 | 19.00 | 13.00 | 9.00 | 6.00 | 4.00 | 3.00 | 2.00 | 2.00 |
| Cashflow From Investing | 86.6% | 50.00 | 27.00 | -350 | -345 | -332 | -319 | -106 | -101 | -82.46 | -74.63 | -38.39 | -22.71 | -35.08 | -41.48 | -42.77 | -39.01 | -33.78 | -24.39 | -6.71 | -5.17 | -3.76 |
| Cashflow From Financing | 7.4% | 11.00 | 10.00 | 16.00 | 20.00 | 24.00 | 34.00 | 35.00 | 34.00 | 514 | 506 | 469 | 460 | 389 | 380 | 415 | 452 | 48.00 | 74.00 | 105 | 93.00 | 21.00 |
TXG Income Statement
2023-06-30Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 146,819 | $ 114,609 | $ 281,104 | $ 229,105 |
| Cost of revenue | 47,207 | 27,704 | 83,102 | 53,182 |
| Gross profit | 99,612 | 86,905 | 198,002 | 175,923 |
| Operating expenses: | ||||
| Research and development | 71,460 | 70,685 | 138,558 | 134,763 |
| Selling, general and administrative | 91,510 | 79,337 | 174,790 | 146,012 |
| Total operating expenses | 162,970 | 150,022 | 313,348 | 280,775 |
| Loss from operations | (63,358) | (63,117) | (115,346) | (104,852) |
| Other income (expense): | ||||
| Interest income | 4,100 | 1,238 | 7,969 | 1,807 |
| Interest expense | (5) | (109) | (24) | (237) |
| Other expense, net | (1,504) | (1,843) | (3,020) | (2,243) |
| Total other income (expense) | 2,591 | (714) | 4,925 | (673) |
| Loss before provision for income taxes | (60,767) | (63,831) | (110,421) | (105,525) |
| Provision for income taxes | 1,647 | 627 | 2,740 | 1,346 |
| Net loss | $ (62,414) | $ (64,458) | $ (113,161) | $ (106,871) |
| Net loss per share, basic (in dollars per share) | $ (0.53) | $ (0.57) | $ (0.97) | $ (0.94) |
| Net loss per share, diluted (in dollars per share) | $ (0.53) | $ (0.57) | $ (0.97) | $ (0.94) |
| Weighted-average shares of common stock used in computing net loss per share, basic (in shares) | 116,707,672 | 113,574,757 | 116,166,776 | 113,272,158 |
| Weighted-average shares of common stock used in computing net loss per share, diluted (in shares) | 116,707,672 | 113,574,757 | 116,166,776 | 113,272,158 |
TXG Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 325,879 | $ 219,746 |
| Marketable securities | 65,506 | 210,238 |
| Restricted cash | 1,500 | 2,633 |
| Accounts receivable, net | 87,685 | 104,211 |
| Inventory | 83,687 | 81,629 |
| Prepaid expenses and other current assets | 18,683 | 16,578 |
| Total current assets | 582,940 | 635,035 |
| Property and equipment, net | 284,913 | 289,328 |
| Restricted cash | 3,474 | 4,974 |
| Operating lease right-of-use assets | 71,049 | 69,882 |
| Goodwill | 4,511 | 4,511 |
| Intangible assets, net | 22,290 | 22,858 |
| Other noncurrent assets | 20,461 | 2,392 |
| Total assets | 989,638 | 1,028,980 |
| Current liabilities: | ||
| Accounts payable | 23,124 | 21,599 |
| Accrued compensation and related benefits | 22,372 | 32,675 |
| Accrued expenses and other current liabilities | 34,088 | 59,779 |
| Deferred revenue | 9,217 | 7,867 |
| Operating lease liabilities | 9,286 | 9,037 |
| Total current liabilities | 98,087 | 130,957 |
| Operating lease liabilities, noncurrent | 90,331 | 86,139 |
| Other noncurrent liabilities | 7,919 | 6,141 |
| Total liabilities | 196,337 | 223,237 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Preferred stock | 0 | 0 |
| Common stock | 2 | 2 |
| Additional paid-in capital | 1,936,750 | 1,839,397 |
| Accumulated deficit | (1,142,482) | (1,029,321) |
| Accumulated other comprehensive loss | (969) | (4,335) |
| Total stockholders’ equity | 793,301 | 805,743 |
| Total liabilities and stockholders’ equity | $ 989,638 | $ 1,028,980 |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.